PAM
STOK icon

Panagora Asset Management’s Stoke Therapeutics STOK Stock Holding History

Panagora Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-104,272
Closed -$1.15M – 1200
2024
Q4 		$1.15M Buy
+104,272
New +$1.28M 0.01% 631

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Panagora Asset Management's STOK Position: Q1 2025 in Review

Panagora Asset Management sold out of Stoke Therapeutics (STOK) in Q1 2025, closing a stake of 104,272 shares — an estimated $1.15M sold.

Panagora Asset Management first reported a position in STOK in Q4 2024 and held it in 1 quarter. The position peaked at $1.15M in Q4 2024. 126 funds tracked by Wall St. Rank hold STOK as of Q1 2025.

  • Panagora Asset Management reported no remaining Stoke Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Panagora Asset Management sold 104,272 Stoke Therapeutics shares in Q1 2025, an estimated $1.15M.
  • Panagora Asset Management first reported a position in Stoke Therapeutics in Q4 2024 and held it in 1 quarter.
  • Panagora Asset Management's Stoke Therapeutics position peaked at $1.15M in Q4 2024.
  • 126 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2025.

Based on Panagora Asset Management's 13F filing for Q1 2025, filed 15 May 2025.